• Mashup Score: 2

    Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

    Tweet Tweets with this article
    • Based on SOLOIST-WHF and SCORED, previously presented at the @AHAMeetings and published in the @NEJM, #sotagliflozin has been approved by the @US_FDA. #cardiotwitter #cardiology #heartfailure #kidneydisease #diabetes @gabrielsteg @cpcannon https://t.co/AOj5DG8Mak via @hcplive

  • Mashup Score: 0

    The U.S. Food and Drug Administration (FDA) has approved Lexicon Pharmaceuticals Inc’s drug for a broad treatment of heart failure, including in adult patients with type 2 diabetes, the company said on Friday.

    Tweet Tweets with this article
    • #Sotagliflozin, a novel agent that inhibits SGLT-1 as well as SGLT2, received marketing approval from the @US_FDA on May 26 for reducing the risk for CV ☠️, 🏥 HF, and urgent heart failure visits in HF patients #CardioTwitter https://t.co/c9Ra9YYXPN

  • Mashup Score: 0

    February 23, 2023 — Lexicon Pharmaceuticals, Inc. announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana.  The following analyses of…

    Tweet Tweets with this article
    • @DAICeditor @ACCinTouch #LexiconPharmaceuticals announced the upcoming presentation of new analyses of results from the #SOLOIST_WHF Phase 3 outcomes #study of its investigational #sotagliflozin product at #ACC23: https://t.co/QF31yGtRrY

  • Mashup Score: 10

    Despite major advances in cardiovascular research over the past decade, women with type 2 diabetes have a high risk of cardiovascular events. Several factors contribute to the poor prognosis for women, including higher levels of frailty and comorbidities, …

    Tweet Tweets with this article
    • 🔥Another good news for #Christmas 🎅🏼#Sotagliflozin on the go! Started the process for #TD2M & #HF approval 💫 1st #SGLT1 & #SGLT2i https://t.co/OTl6ZT0C2O @DLBHATTMD @gbiondizoccai @gcfmd @ShelleyZieroth @SABOURETCardio @iamritu @FrancescoPaneni @stefanocarugo @JavedButler1 https://t.co/Sd1eLqhCmv

  • Mashup Score: 1

    CHICAGO — The dual SGLT inhibitor sotagliflozin reduced 30- and 90-day rates of CV mortality and HF-related events when administered before hospital discharge after an episode of worsening HF, according to new data from the SOLOIST trial.Approximately 25% of patients are readmitted within 30 days of a hospital discharge for a worsening HF episode and nearly half of such patients are

    Tweet Tweets with this article
    • The dual SGLT inhibitor #sotagliflozin reduced 30- and 90-day rates of CV mortality and #HeartFailure-related events when administered before discharge after an episode of worsening HF @umichmedicine @AHAMeetings @EndocrineToday #AHA22 #cardiotwitter https://t.co/EUFh3UTYrZ